Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 9388134 | Orange Book listed patent (incl. pediatric exclusivity extension) | Novartis AG | May 8, 2027 | 0.9y left |
| 8877938 | Drug substance & product patent (incl. pediatric exclusivity extension) | Novartis AG | Nov 27, 2027 | 1.4y left |
| 11135192 | Orange Book listed patent | Novartis AG | Aug 22, 2033 | 7.2y left |
| 9517226 | Orange Book listed patent | Novartis AG | Aug 22, 2033 | 7.2y left |
| 9937143 | Orange Book listed patent | Novartis AG | Aug 22, 2033 | 7.2y left |
| 11058667 | Orange Book listed patent | Novartis AG | May 9, 2036 | 9.9y left |
Related Drug Patent Expirations
0 patents · Novartis AG
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
3 patents · earliest expires 2027 · Pfizer Inc.
44 patents · earliest expires 2027 · Pharmacyclics LLC
15 patents · earliest expires 2027 · Boehringer Ingelheim
12 patents · earliest expires 2027 · AstraZeneca AB
The Entresto record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how Entresto sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Entresto is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.